Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on April 15, 2019. The registrant is incorporated in California and is designated as an emerging growth company. The report addresses corporate governance matters regarding the 2019 Annual Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding shareholder meetings and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the Board of Directors setting the date for the 2019 Annual Meeting of Shareholders to July 10, 2019. Additionally, the deadline for shareholders to submit proposals or director nominations for inclusion in proxy materials is set for April 29, 2019.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various factors. Specific risks are referenced in the company's Form 10-K under the "Risk Factors" heading. No specific financial guidance or management commentary on operations is provided in this text.
Key Facts for Investor Verification
- Annual Meeting Date: July 10, 2019.
- Deadline for Shareholder Proposals/Nominations: April 29, 2019.
- Submission Requirement: Nominating shareholders must submit notice on Schedule 14N.
- Company Status: Emerging Growth Company.
- Financial Data: None included in this specific filing; refer to Form 10-K for financials.